MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Pacira BioSciences Cost of Revenue 2011-2026 | PCRX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Pacira BioSciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170 M | 185 M | 199 M | 140 M | 117 M | 107 M | 86.8 M | 87.9 M | 110 M | 71.8 M | 77.4 M | 54.8 M | 32.1 M | 16.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 199 M | 16.7 M | 104 M |
Quarterly Cost of Revenue Pacira BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.3 M | 40.9 M | 34.3 M | - | 38.9 M | 44.3 M | 47.4 M | - | 39.8 M | 48.2 M | 49 M | - | 50.7 M | 50.6 M | 36.1 M | - | 34.7 M | 35.2 M | 31.3 M | 35.3 M | 30 M | 22.3 M | 29.7 M | 31.9 M | 22.3 M | 25.2 M | 27.3 M | 24 M | 19.1 M | 20.9 M | 22.9 M | 21.3 M | 18.2 M | 23.8 M | 24.6 M | 23.6 M | 43.2 M | 23.1 M | 20.3 M | 19.4 M | 15.9 M | 18.9 M | 17.6 M | 77.4 M | 20.4 M | 20 M | 18.1 M | 18.4 M | 14.8 M | 10.2 M | 11.4 M | 9.67 M | 9.29 M | 6.68 M | 6.5 M | - | 3.36 M | 3.12 M | 3.67 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 77.4 M | 3.12 M | 26.5 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
6.19 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
6.21 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.02 | - | $ 110 M |  Canada |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
35.4 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
100 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Jupiter Wellness
JUPW
|
3.15 M | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
67.9 M | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
6.51 M | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.44 | -4.64 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
2.76 B | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
74.9 M | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Veru
VERU
|
11 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
480 M | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
8.99 B | $ 13.51 | - | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zomedica Corp.
ZOM
|
10.4 M | - | -0.21 % | $ 98 M | USA |